Menu
Search
|

Menu

Close
X

Juno Therapeutics Inc JUNO.OQ (NASDAQ Stock Exchange Global Select Market)

86.58 USD
+0.02 (+0.02%)
As of Feb 23
chart
Previous Close 86.56
Open 86.59
Volume 388,568
3m Avg Volume 908,879
Today’s High 86.59
Today’s Low 86.55
52 Week High 86.75
52 Week Low 19.62
Shares Outstanding (mil) 114.17
Market Capitalization (mil) 9,885.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.92 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY17
41
FY16
79
FY15
18
EPS (USD)
FY17
-1.756
FY16
-2.424
FY15
-2.724
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
92.76
8.35
Price to Book (MRQ)
vs sector
8.56
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
2.85
15.84
LT Debt to Equity (MRQ)
vs sector
2.85
12.39
Return on Investment (TTM)
vs sector
-26.97
13.63
Return on Equity (TTM)
vs sector
-31.25
15.39

EXECUTIVE LEADERSHIP

Howard Pien
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Hans Bishop
President, Chief Executive Officer, Director, Since 2013
Salary: $483,894.00
Bonus: --
Sunil Agarwal
President of Research & Development, Since 2017
Salary: --
Bonus: --
Steven Harr
Chief Financial Officer, Head of Corporate Development, Since 2014
Salary: $404,954.00
Bonus: --
Hyam Levitsky
Executive vice president - Research, chief scientific officer, Since 2015
Salary: $390,692.00
Bonus: $28,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

400 Dexter Ave N Ste 1200
SEATTLE   WA   98109-4703

Phone: +1206.5821600

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

SPONSORED STORIES